Related Experiment Video
Updated: Aug 22, 2025
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.0K
Deucravacitinib in moderate-to-severe psoriasis
Alan Vu1, Victoria Maloney1, Kenneth B Gordon1
1Department of Dermatology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA.
Immunotherapy
|November 14, 2022
Summary
Deucravacitinib, a new oral therapy, effectively treats moderate to severe plaque psoriasis. This selective TYK2 inhibitor shows significant Psoriasis Area and Severity Index score reductions in clinical trials.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Psoriasis is a chronic inflammatory disease impacting millions globally, significantly affecting patient quality of life.
- Biologics are common treatments for moderate to severe psoriasis, but oral small-molecule therapies have been limited.
- Tyrosine Kinase 2 (TYK2) is a key mediator in inflammatory pathways relevant to psoriasis.
Purpose of the Study:
- To evaluate the efficacy and safety of deucravacitinib, a novel oral selective TYK2 inhibitor, in patients with moderate to severe plaque psoriasis.
- To compare deucravacitinib's performance against placebo and apremilast in clinical trials.
Main Methods:
- Phase III clinical trials were conducted to assess deucravacitinib in moderate to severe plaque psoriasis patients.
- Patients received deucravacitinib 6 mg daily, with comparisons to placebo and apremilast 30 mg twice daily.
- The Psoriasis Area and Severity Index (PASI) score was a primary efficacy endpoint.
Main Results:
- Over 50% of patients on deucravacitinib achieved a ≥75% reduction in PASI score at 16 weeks.
- This contrasts with 9-13% for placebo and 35-41% for apremilast.
- Deucravacitinib demonstrated a favorable safety and efficacy profile in clinical development.
Conclusions:
- Deucravacitinib is an effective and safe oral treatment option for moderate to severe plaque psoriasis.
- Its selective inhibition of TYK2 offers a targeted approach to managing this inflammatory condition.
- The study supports deucravacitinib as a valuable addition to psoriasis treatment paradigms.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
248
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
248
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
212
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
212
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
188
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
188
01:29Inflammatory Bowel Disease IV: Pharmacological Management
169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
169
01:29Drugs for Treatment of Ulcerative Colitis in IBD
220
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
220
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
636
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
636